{"name":"ASLAN Pharmaceuticals","slug":"aslan-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ASLAN003 ACTIVE","genericName":"ASLAN003 ACTIVE","slug":"aslan003-active","indication":"Other","status":"phase_1"},{"name":"ASLAN004","genericName":"ASLAN004","slug":"aslan004","indication":"Other","status":"phase_2"},{"name":"Farudodstat","genericName":"Farudodstat","slug":"farudodstat","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ASLAN003","genericName":"ASLAN003","slug":"aslan003","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"ASLAN003","genericName":"ASLAN003","slug":"aslan003","phase":"phase_2","mechanism":"ASLAN003 is a monoclonal antibody targeting the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"ASLAN003 ACTIVE","genericName":"ASLAN003 ACTIVE","slug":"aslan003-active","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASLAN004","genericName":"ASLAN004","slug":"aslan004","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Farudodstat","genericName":"Farudodstat","slug":"farudodstat","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNeWEyc0ZSQ29fczhyMHUxMG1ZUmk1YmM5bVdSOE1kOTFqQl9PRWZOV1FyMXJFdTZjSmNZdUwta3gySjJmN09xbkYydDhVQnRGU3E4RTJvb3Q1NnZSbzdLVmdoNTBhQUROT2hrbWRza3NFb2YzR1QtV3htZkFlbmNyWGM0anBEcXdzQ3NnZVpzdTVRX0FOenZJeDA1UVVWVTluai1yWS1QMWRWNExWTkxSMnBJZUdQUDE1Q1h1VGcyam1mdDlNbDJydTVTenUzZ1ZieWZkZGNKeVhJaXVway05RWxucnhjMkxMZFl4bkpleHhtaEJYQlhHXzhYcEt6LXpUVzVWLXdjUDFGbEl0UjBlenpORUp3Y3hqZFdUeFBzaW9XM2xnSV9IOG1VLXNQN3hZb1pPcEtfR0dZakZsRXFkeFBpdURTX3pDa1BXT1FpZjRmLXM?oc=5","date":"2025-09-17","type":"pipeline","source":"PR Newswire","summary":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight - PR Newswire","headline":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPaUZvam1nb2ZBSUk5Wkh2bWhJU2NlVjh5czF2LWJ4MVRUeEFURlh4eDl2ZU1BdUVOdGtsV1M0VHIxdjRwMmVNU0xNd0I0cDJ5M05sYTV3VXFScFhLUk9hNS1zNmZudDBNZy1Pa3lkY0dQeTc2Yzd5U2RxVmFYRVlZYmJrX2dHakxEenJHUUl3cU9LQ2lDNktLbnl3dkRQaGk3cjB3?oc=5","date":"2024-07-19","type":"regulatory","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Hengrui's FDA reprimands; Sanofi's India site expansion; Aslan's downfall - Fierce Pharma","headline":"Fierce Pharma Asia—Hengrui's FDA reprimands; Sanofi's India site expansion; Aslan's downfall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNNW9pZjhDdS1iX1ZyNmV4R05xTV96ZWlqVmVwLW42ejZtR2RLd012MGtGZ3NGTnZzd09LUGJxVERCZXdZZVZXYWxKQlRtQnZUWjRBdDZEUDF0Z2ZiNVdHTk9aSl9oYW9JNElXU2t3aVNtempsdThNZVBlRFRwT0RjMDBZZnBEMlYxdTFtejdmTHRaSTdWWVNXbXpvU05fbUthS1M1b3RWS1BqSjRDWEE?oc=5","date":"2024-07-17","type":"pipeline","source":"Fierce Biotech","summary":"Aslan’s dream of challenging Dupixent dies as cash-strapped biotech winds down - Fierce Biotech","headline":"Aslan’s dream of challenging Dupixent dies as cash-strapped biotech winds down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxQUWpQeThVYzhWcmVGOFVQSU52cTMyTWkwcE5sdmRYWjV6TXJzeTlIM3c4OHBScmxSZjVCVUhndExOdnBRR0xjdi1oQW9jVGNPdGlWQW5lZmVYdk01SjhBYlEwOE8zUDA0NTlYVTB1U1BwaXJLMjlrcDlsUlZqcmlvTFdYcHpKRWhHbk9TcGgxR3JLWDlZbURDWFBTSF94dnhaSW9LODFQTzJFQmd6NEllTVJ2TnlNeWFORHlBM21oRDJ6eEFRSGVkS2pwaWVsQ3d0S0Q4NjhzSmgwemc2NXdRdk13OGN1NWkxQ0lBTVk1eHZxYWJ2aEdETFRmRWxkT3cySURzU2RNVDE0WGgyRnBkYVAyaG5QcVo4SFJVeHNab29lSG1PM3NHeDdWeWVrX3dSNVMtdEdsXzdzR2hmbTNNQlZrQnlSZnZIck1Gc3Rna0FxN01MVWcwME5jU2lka00?oc=5","date":"2024-07-17","type":"pipeline","source":"GlobeNewswire","summary":"ASLAN Pharmaceuticals Announces it Has Filed for Voluntary - GlobeNewswire","headline":"ASLAN Pharmaceuticals Announces it Has Filed for Voluntary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQM0xOMFEtSzBFckJTVXdrQnlnY1dGck9IdllNd0dVODR2TVhRZVZKczcza2hfT0xsQnQwMFdxaGtYU0x0dVZNUEp6ODBsRXAzLXpXVEJTdUlmUWNRbHBmMUFyUlduTHhQeUl2dk1sX05OalpoRkxVSHRzMDJIeGRTUmM4NGE1TWpWWWZubGloMzFaRXpBRUgw?oc=5","date":"2024-07-15","type":"pipeline","source":"Yahoo Finance","summary":"ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - Yahoo Finance","headline":"ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNb2Z3MWVPRHhjV3drb3gtaFFwMDJkamRsaENtSmlXZ1Q1RVBlLWxMaDQyMHVHQzVFTW43VGttLXJGUVRvTVF6OTBDdm1HenRMLXgtdko4NVhVZFFjc1Y5NW9QNmpsU0g0SHZPUnd1ei1qaHZjNDdQNGtUNlBFb3dBSEtrdnltLVV2T3BWSGU5dmNqLWRpVF83ZjdyU3pJRTl3X3NZcE1fNVB4aXdMUk8tRnRVMGZac0MwVXhYb09JSDAtUEVYWnRGVldhcGUxeWhnRG1CaWdHSVhoV2l4LVE?oc=5","date":"2024-05-02","type":"deal","source":"Dermatology Times","summary":"ASLAN Expands Collaboration with Zenyaku to Investigate Eblasakimab’s MOA Compared to Other Biologics in AD - Dermatology Times","headline":"ASLAN Expands Collaboration with Zenyaku to Investigate Eblasakimab’s MOA Compared to Other Biologics in AD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFA2aTljQ2hCQ2ozVW5LelJtUkxDY3FKdDBLaUR5by15bjYybkVIeXJiMHQyb1FSa3NsMUZEUFZXbFA3QUdQWDFVVGl6Tmc5QzNzRGx3b242ZTc2UFl4Mk1FRHBNc29PeFR0cmE4WElSYVN1QTRoa1NJWTl4QQ?oc=5","date":"2024-04-23","type":"trial","source":"Clinical Trials Arena","summary":"ASLAN reports interim data from atopic dermatitis drug trial - Clinical Trials Arena","headline":"ASLAN reports interim data from atopic dermatitis drug trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOTXdQR3ZRWVJmX2ZZQ0xJLXdMLWgyYXlZdU81blA5NUFMSF8zRTd1ZXdtaDZNOWpBblQzUnIwZmo3SlgxQk9QTU9vN1FlMGtCU21xcUR5V1BmWEpUZGotbUx4TzZrNGNxdGxyQ0puYy1heV9jSkFCcFVoREF4LUg4MVlzYjNlQ21qNHZJNWtXVVh1dlBabDRtMzRSbFNNdDk3VndSbnB0N1pCTlRvQmw5V3l6akJ5bkViVlY2c2hmdktVVUVYaXZPZm40aWhhT214UnU4MUx3MkNkQjZBUS1Mb3VCZzRoVGtqQ2VvalU5R3ItM3JXZjZsYWpCOFNfVklsVWRYdFZDbE43NFF2Q2lOSjBBWjlvOG0tRFV0QVZjNzgtX2p4Zmx3TDBmRQ?oc=5","date":"2023-02-24","type":"pipeline","source":"GlobeNewswire","summary":"ASLAN Pharmaceuticals Announces $20M Private Placement Led - GlobeNewswire","headline":"ASLAN Pharmaceuticals Announces $20M Private Placement Led","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNUjVOclBCSmJvN2Q0MXJ1QWo2VG1Sc2lqclE2MlZJRWFkTlpqbnNEaVpBbzFXeWVWMDNLREstT1BsRmhSY1ZOdWtmT3RjWm9ZZW5nWW5leEhIYnIxLTlla2hweHBFMGMtVkEzTUhJc1VtYzBlbHAxX19YUURBX0k5aUh5d08zUQ?oc=5","date":"2022-07-15","type":"deal","source":"Penn Global","summary":"Collaboration & Productivity at ASLAN Pharma - Penn Global","headline":"Collaboration & Productivity at ASLAN Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNLWx6SVoyWWhOWEtNVHpvb213UzgyaFF2SmZFQXhEcWRhMDF4WG8tWjY3SHcyaEtKaVV6RzdJbGIyNldTcmVuX2FaaG5FaXM0WS1sZ1hQTENsOFVtNGl6OElxWkk0QlVQbWx1R3p0NFdYYnVlN19VUW9sY3pxd2RaWUNQcS1JbTRUa2tPb29PcVNuQ0ZS?oc=5","date":"2019-11-11","type":"pipeline","source":"Fierce Biotech","summary":"Aslan's varlitinib hopes fade after latest failure - Fierce Biotech","headline":"Aslan's varlitinib hopes fade after latest failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNX1hsSF9vN1laSGxuOTR1TGdpbzBBeHBCdno4SXRITkV2WmVYV3R3REppSHZJWWNBT25waTBMTXBiZ0szLUNJenU4OEFsZFVEYm92TDNtdkpUajhiekNHUHpqUjNEbW1NZEY2eW9VaWhmUjFBbnozZjN4ajdsX0RoaTRVTTl3Zk56T2dNeHpGdU1BRl9mN1BlXzNWd0htY2pWT1JIcjJZZ1BpaXpWZ21yVy1EYTJ0ZXB2ZmhvX0xvVGVJVUZoRHc?oc=5","date":"2019-01-18","type":"deal","source":"Fierce Pharma","summary":"FiercePharmaAsia—Gilead’s clinical VP; Aurobindo buys Spectrum assets; Aslan’s lead drug - Fierce Pharma","headline":"FiercePharmaAsia—Gilead’s clinical VP; Aurobindo buys Spectrum assets; Aslan’s lead drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPNVZ5UTR1aDRNbjJIdUJzeGQyWUxSTzRJYTJtdlptRktCa2Izd3VkZFZlQjJ0cTBwNDFlTGR2LUJBMFN3T0ZHaktjSXAwT3M1Xy1uOEJpWG9UTTQ3bGNOWHJpZTBYVGFxWWdyQVV6bGRDRlp2aTh1cGdvZHNKSWE3RzdMS2lfUlJYczdsTXJGeTJhZDBy?oc=5","date":"2016-07-12","type":"pipeline","source":"Asian Scientist Magazine","summary":"ASLAN Pharma Raises US$23 Million In Pre-IPO Financing Round - Asian Scientist Magazine","headline":"ASLAN Pharma Raises US$23 Million In Pre-IPO Financing Round","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}